ovarian cancer | pharmaphorum

Wednesday 20 May 2026

ovarian cancer

News

Ignota's co-founder and chief executive, Sam Windsor

Ignota vacuums up Kronos Bio's drug programmes

Ignota Labs of the UK has acquired all of the clinical-stage assets in Kronos Bio's pipeline, after the US firm ceased operations earlier this year.

News

US and UK flags meet on a diagonal, with grey border line

AbbVie joins BMS in taking a hard line on UK drug pricing

AbbVie has said it may not launch its ovarian cancer therapy Elahere in the UK if a viable NHS price cannot be agreed with NICE.

News

UK MHRA green lights AbbVie’s ELAHERE for ovarian cancer

UK MHRA green lights AbbVie’s ELAHERE for ovarian cancer

AbbVie has secured UK marketing authorisation for ELAHERE (mirvetuximab soravtansine), the first antibo

Oncology

pharmaphorum podcast Episode 185a - Dr Stacy Lindborg

IMUNON at ASCO 2025: Changing the micro-tumour environment i...

News

AbbVie builds the case for ovarian cancer drug Elahere

AbbVie builds the case for ovarian cancer drug Elahere

AbbVie hopes for another lift to its fast-growing ovarian cancer drug Elahere with new survival data.

News

Jane Chung

Sutro puts lead ADC on hold, cuts staff and changes CEO

Sutro has shelved its lead drug for ovarian cancer and turned its attention to three preclinical candidates in a major shake-up of its business.